JP7308190B2 - 抗ｃｄ４７及び抗ｐｄ－ｌ１による卵巣癌の処置 - Google Patents

抗ｃｄ４７及び抗ｐｄ－ｌ１による卵巣癌の処置 Download PDF

Info

Publication number
JP7308190B2
JP7308190B2 JP2020521860A JP2020521860A JP7308190B2 JP 7308190 B2 JP7308190 B2 JP 7308190B2 JP 2020521860 A JP2020521860 A JP 2020521860A JP 2020521860 A JP2020521860 A JP 2020521860A JP 7308190 B2 JP7308190 B2 JP 7308190B2
Authority
JP
Japan
Prior art keywords
antibody
dose
subject
combination
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020521860A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021500336A5 (enExample
JP2021500336A (ja
Inventor
クリス ヒデミ ミズフネ タキモト
マーク ピン チャオ
イェンス－ペーター フォルクマール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forty Seven LLC
Original Assignee
Forty Seven LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forty Seven LLC filed Critical Forty Seven LLC
Publication of JP2021500336A publication Critical patent/JP2021500336A/ja
Publication of JP2021500336A5 publication Critical patent/JP2021500336A5/ja
Priority to JP2022186496A priority Critical patent/JP7474827B2/ja
Application granted granted Critical
Publication of JP7308190B2 publication Critical patent/JP7308190B2/ja
Priority to JP2024003136A priority patent/JP2024024121A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020521860A 2017-10-18 2018-10-18 抗ｃｄ４７及び抗ｐｄ－ｌ１による卵巣癌の処置 Active JP7308190B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022186496A JP7474827B2 (ja) 2017-10-18 2022-11-22 抗ｃｄ４７及び抗ｐｄ－ｌ１による卵巣癌の処置
JP2024003136A JP2024024121A (ja) 2017-10-18 2024-01-12 抗ｃｄ４７及び抗ｐｄ－ｌ１による卵巣癌の処置

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762574073P 2017-10-18 2017-10-18
US62/574,073 2017-10-18
PCT/US2018/056442 WO2019079549A1 (en) 2017-10-18 2018-10-18 TREATMENT OF OVARY CANCER BY ANTI-CD47 AND ANTI-PD-L1

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022186496A Division JP7474827B2 (ja) 2017-10-18 2022-11-22 抗ｃｄ４７及び抗ｐｄ－ｌ１による卵巣癌の処置

Publications (3)

Publication Number Publication Date
JP2021500336A JP2021500336A (ja) 2021-01-07
JP2021500336A5 JP2021500336A5 (enExample) 2021-10-07
JP7308190B2 true JP7308190B2 (ja) 2023-07-13

Family

ID=64402251

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020521860A Active JP7308190B2 (ja) 2017-10-18 2018-10-18 抗ｃｄ４７及び抗ｐｄ－ｌ１による卵巣癌の処置
JP2022186496A Active JP7474827B2 (ja) 2017-10-18 2022-11-22 抗ｃｄ４７及び抗ｐｄ－ｌ１による卵巣癌の処置
JP2024003136A Withdrawn JP2024024121A (ja) 2017-10-18 2024-01-12 抗ｃｄ４７及び抗ｐｄ－ｌ１による卵巣癌の処置

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022186496A Active JP7474827B2 (ja) 2017-10-18 2022-11-22 抗ｃｄ４７及び抗ｐｄ－ｌ１による卵巣癌の処置
JP2024003136A Withdrawn JP2024024121A (ja) 2017-10-18 2024-01-12 抗ｃｄ４７及び抗ｐｄ－ｌ１による卵巣癌の処置

Country Status (12)

Country Link
US (1) US20210047416A1 (enExample)
EP (2) EP4194470A1 (enExample)
JP (3) JP7308190B2 (enExample)
KR (1) KR20200070341A (enExample)
CN (1) CN111315783A (enExample)
AU (1) AU2018351007B2 (enExample)
CA (1) CA3078430A1 (enExample)
ES (1) ES2938652T3 (enExample)
PL (1) PL3697819T3 (enExample)
PT (1) PT3697819T (enExample)
SI (1) SI3697819T1 (enExample)
WO (1) WO2019079549A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114716552B (zh) 2016-01-11 2024-05-24 四十七公司 人源化、小鼠或嵌合抗cd47单克隆抗体
CN111247172B (zh) 2017-10-18 2023-11-14 四十七公司 基于抗cd47剂的卵巢癌疗法
EP4129336B1 (en) 2018-02-12 2025-05-07 Forty Seven, LLC Anti-cd47 agent-based treatment of cd20-positive cancer
EP3969484A4 (en) * 2019-05-17 2023-07-05 Nanjing GenScript Biotech Co., Ltd. ANTI-CD47/ANTI-PD-L1 MULTIPLE ANTIGEN BINDING PROTEINS AND METHODS OF USE
US11702474B2 (en) 2019-12-17 2023-07-18 Pfizer Inc. Antibodies specific for CD47, PD-L1, and uses thereof
CN120437288A (zh) * 2019-12-24 2025-08-08 正大天晴药业集团南京顺欣制药有限公司 治疗卵巢癌的药物组合
WO2021170082A1 (zh) * 2020-02-28 2021-09-02 南京圣和药业股份有限公司 抗cd47/抗pd-l1抗体及其应用
CN116670289A (zh) * 2021-01-08 2023-08-29 北京韩美药品有限公司 抗pd-l1/抗cd47天然抗体结构样异源二聚体形式双特异抗体及其制备

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017127707A1 (en) 2016-01-21 2017-07-27 The Board Of Trustees Of The Leland Stanford Junior University Treatment of cancer with combinations of immunoregulatory agents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2616010T3 (es) 2010-05-14 2017-06-09 The Board Of Trustees Of The Leland Stanford Junior University Anticuerpos monoclonales humanizados y quiméricos a CD47
AU2014238105B2 (en) 2013-03-15 2018-11-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for achieving therapeutically effective doses of anti-CD47 agents
CA2961774C (en) * 2014-10-07 2023-05-23 Immunomedics, Inc. Neoadjuvant use of antibody-drug conjugates
TWI595006B (zh) * 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
WO2017019767A1 (en) * 2015-07-27 2017-02-02 Myosotis, Llc Inhibition of CXCL12 in Cancer Immunotherapy
CA2998644A1 (en) * 2015-09-18 2017-03-23 Arch Oncology, Inc. Therapeutic cd47 antibodies
US20190290759A1 (en) * 2015-12-28 2019-09-26 Syndax Pharmaceuticals, Inc. Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of ovarian cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017127707A1 (en) 2016-01-21 2017-07-27 The Board Of Trustees Of The Leland Stanford Junior University Treatment of cancer with combinations of immunoregulatory agents

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
Cancer Research, 2016, Vol.76, No.14, Abstract 4001，https://doi.org/10.1158/1538-7445.AM2016-4001
European Journal of Cancer, 2014, Vol.50, Suppl.5, p.S13，DOI 10.1016/S0959-8049(14)50050-0
Gynecologic Oncology Reports, 2017.06.27, Vol.21, pp.78-80，http://dx.doi.org/10.1016/j.gore.2017.06.013
Gynecologic Oncology, 2016, Vol.143, No.2, pp.393-397，doi:10.1016/j.ygyno.2016.08.325
Oncotarget, 2017.03, Vol.8, No.24, pp.39021-39032
PLoS ONE, 2015, Vol.10, No.9, Article No.e0137345, pp.1-23，doi:10.1371/journal.pone.0137345
PNAS, 2012, Vol.109, No.17, pp.6662-6667，https://doi.org/10.1073/pnas.1121623109
PNAS, 2016, Vol.113, No.19, pp.E2646-E2654

Also Published As

Publication number Publication date
JP7474827B2 (ja) 2024-04-25
PT3697819T (pt) 2023-02-20
ES2938652T3 (es) 2023-04-13
EP4194470A1 (en) 2023-06-14
JP2023014162A (ja) 2023-01-26
US20210047416A1 (en) 2021-02-18
KR20200070341A (ko) 2020-06-17
EP3697819A1 (en) 2020-08-26
AU2018351007B2 (en) 2024-05-16
AU2018351007A1 (en) 2020-05-21
WO2019079549A1 (en) 2019-04-25
CN111315783A (zh) 2020-06-19
EP3697819B1 (en) 2022-11-16
SI3697819T1 (sl) 2023-01-31
JP2024024121A (ja) 2024-02-21
CA3078430A1 (en) 2019-04-25
PL3697819T3 (pl) 2023-03-06
JP2021500336A (ja) 2021-01-07

Similar Documents

Publication Publication Date Title
JP7308190B2 (ja) 抗ｃｄ４７及び抗ｐｄ－ｌ１による卵巣癌の処置
US20250066473A1 (en) Treatment of cancer with combinations of immunoregulatory agents
US20240218077A1 (en) Anti-cd47 agent-based treatment of cd20-positive cancer
EP3013350B1 (en) Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases
JP2021181482A (ja) 中枢神経系新生物における免疫チェックポイント阻害剤の使用
JP7308191B2 (ja) 抗ｃｄ４７剤ベースの卵巣癌療法
HK40092424A (en) Treatment of ovarian cancer with anti-cd47 and anti-pd-l1
HK40036031A (en) Treatment of ovarian cancer with anti-cd47 and anti-pd-l1
HK40036031B (en) Treatment of ovarian cancer with anti-cd47 and anti-pd-l1
HK40032879A (en) Treatment of ovarian cancer with anti-cd47 and anti-pd-l1
US9868792B2 (en) Methods of enhancing anti-tumor immunity by administering antibodies to the CCRL2 chemerin receptor
HK40077720A (en) Treatment of cancer with combinations of immunoregulatory agents
NZ755091B2 (en) Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200909

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20201217

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20201217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210824

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210824

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230411

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230630

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230703

R150 Certificate of patent or registration of utility model

Ref document number: 7308190

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350